![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
CytRx, Advanced BioScience Laboratories and the University of Massachusetts Medical School has completed enrollment of healthy volunteers in a three-arm Phase I clinical trial for a novel HIV DNA vaccine.
The primary objective of the Phase I clinical trial is to determine the safety and tolerability of different dosages and routes of administration of the DNA vaccine, and a fixed dosage and route of administration of an HIV protein boost.
The vaccine strategy is to assess in human volunteers whether a DNA vaccine with a protein boost can stimulate both antibody and T-cell immune responses to the virus as previously demonstrated in animal models. To date, the vaccine has been well-tolerated in humans.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct